On the ESMO TNBC poster, on the lower left, is "Table 1. Demographic Table," with information about the patients. Under the heading "Leronlimab Dose" they list 350mg (N-10), 525mg (N-15) and 700mg (N-3). Next to the 525mg dose they write in parentheses "5 increased from 350mg."

I mangled/mis-interpreted the numbers in my earlier post... The way I read it now is there were originally 15 on 350mg and 10 on 525mg, but they bumped up five to 525mg, for the final totals listed. But getting back to Skezan's original concern, it appears that 10 out of the 12 who showed an increase in CTCs/CAMLs after treatment with leronlimab likely got an ineffective dose.